Cargando…

Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics

[Image: see text] The application of lipid-based drug delivery technologies for bioavailability enhancement of drugs has led to many successful products in the market for clinical use. Recent studies on amine-containing heterolipid-based synthetic vectors for delivery of siRNA have witnessed the Uni...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhumal, Dinesh M., Patil, Pankaj D., Kulkarni, Raghavendra V., Akamanchi, Krishnacharya G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745400/
https://www.ncbi.nlm.nih.gov/pubmed/33344856
http://dx.doi.org/10.1021/acsomega.0c04931
_version_ 1783624597457862656
author Dhumal, Dinesh M.
Patil, Pankaj D.
Kulkarni, Raghavendra V.
Akamanchi, Krishnacharya G.
author_facet Dhumal, Dinesh M.
Patil, Pankaj D.
Kulkarni, Raghavendra V.
Akamanchi, Krishnacharya G.
author_sort Dhumal, Dinesh M.
collection PubMed
description [Image: see text] The application of lipid-based drug delivery technologies for bioavailability enhancement of drugs has led to many successful products in the market for clinical use. Recent studies on amine-containing heterolipid-based synthetic vectors for delivery of siRNA have witnessed the United States Food and Drug Administration (USFDA) approval of the first siRNA drug in the year 2018. The studies on various synthetic lipids investigated for delivery of such nucleic acid therapeutics have revealed that the surface pK(a) of the constructed nanoparticles plays an important role. The nanoparticles showing pK(a) values within the range of 6–7 have performed very well. The development of high-performing lipid vectors with structural diversity and falling within the desired surface pK(a) is by no means trivial and requires tedious trial and error efforts; therefore, a practical solution is called for. Herein, an attempt to is made provide a solution by predicting the statistically significant pK(a) through a predictive quantitative structure–activity relationship (QSAR) model. The QSAR model has been constructed using a series of 56 amine-containing heterolipids having measured pK(a) values as a data set and employing a partial least-squares regression coupled with stepwise (SW-PLSR) forward algorithm technique. The model was tested using statistical parameters such as r(2), q(2), and pred_r(2), and the model equation explains 97.2% (r(2) = 0.972) of the total variance in the training set and it has an internal (q(2)) and an external (pred_r(2)) predictive ability of ∼83 and ∼63%, respectively. The model was validated by synthesizing a series of designed heterolipids and comparing measured surface pK(a) values of their nanoparticle assembly using a 2-(p-toluidino)-6-napthalenesulfonic acid (TNS) assay. Predicted and measured surface pK(a) values of the synthesized heterolipids were in good agreement with a correlation coefficient of 93.3%, demonstrating the effectiveness of this QSAR model. Therefore, we foresee that our developed model would be useful as a tool to cut short tedious trial and error processes in designing new amine-containing heterolipid vectors for delivery of nucleic acid therapeutics, especially siRNA.
format Online
Article
Text
id pubmed-7745400
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-77454002020-12-18 Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics Dhumal, Dinesh M. Patil, Pankaj D. Kulkarni, Raghavendra V. Akamanchi, Krishnacharya G. ACS Omega [Image: see text] The application of lipid-based drug delivery technologies for bioavailability enhancement of drugs has led to many successful products in the market for clinical use. Recent studies on amine-containing heterolipid-based synthetic vectors for delivery of siRNA have witnessed the United States Food and Drug Administration (USFDA) approval of the first siRNA drug in the year 2018. The studies on various synthetic lipids investigated for delivery of such nucleic acid therapeutics have revealed that the surface pK(a) of the constructed nanoparticles plays an important role. The nanoparticles showing pK(a) values within the range of 6–7 have performed very well. The development of high-performing lipid vectors with structural diversity and falling within the desired surface pK(a) is by no means trivial and requires tedious trial and error efforts; therefore, a practical solution is called for. Herein, an attempt to is made provide a solution by predicting the statistically significant pK(a) through a predictive quantitative structure–activity relationship (QSAR) model. The QSAR model has been constructed using a series of 56 amine-containing heterolipids having measured pK(a) values as a data set and employing a partial least-squares regression coupled with stepwise (SW-PLSR) forward algorithm technique. The model was tested using statistical parameters such as r(2), q(2), and pred_r(2), and the model equation explains 97.2% (r(2) = 0.972) of the total variance in the training set and it has an internal (q(2)) and an external (pred_r(2)) predictive ability of ∼83 and ∼63%, respectively. The model was validated by synthesizing a series of designed heterolipids and comparing measured surface pK(a) values of their nanoparticle assembly using a 2-(p-toluidino)-6-napthalenesulfonic acid (TNS) assay. Predicted and measured surface pK(a) values of the synthesized heterolipids were in good agreement with a correlation coefficient of 93.3%, demonstrating the effectiveness of this QSAR model. Therefore, we foresee that our developed model would be useful as a tool to cut short tedious trial and error processes in designing new amine-containing heterolipid vectors for delivery of nucleic acid therapeutics, especially siRNA. American Chemical Society 2020-11-30 /pmc/articles/PMC7745400/ /pubmed/33344856 http://dx.doi.org/10.1021/acsomega.0c04931 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Dhumal, Dinesh M.
Patil, Pankaj D.
Kulkarni, Raghavendra V.
Akamanchi, Krishnacharya G.
Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
title Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
title_full Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
title_fullStr Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
title_full_unstemmed Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
title_short Experimentally Validated QSAR Model for Surface pK(a) Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
title_sort experimentally validated qsar model for surface pk(a) prediction of heterolipids having potential as delivery materials for nucleic acid therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745400/
https://www.ncbi.nlm.nih.gov/pubmed/33344856
http://dx.doi.org/10.1021/acsomega.0c04931
work_keys_str_mv AT dhumaldineshm experimentallyvalidatedqsarmodelforsurfacepkapredictionofheterolipidshavingpotentialasdeliverymaterialsfornucleicacidtherapeutics
AT patilpankajd experimentallyvalidatedqsarmodelforsurfacepkapredictionofheterolipidshavingpotentialasdeliverymaterialsfornucleicacidtherapeutics
AT kulkarniraghavendrav experimentallyvalidatedqsarmodelforsurfacepkapredictionofheterolipidshavingpotentialasdeliverymaterialsfornucleicacidtherapeutics
AT akamanchikrishnacharyag experimentallyvalidatedqsarmodelforsurfacepkapredictionofheterolipidshavingpotentialasdeliverymaterialsfornucleicacidtherapeutics